Status: Not yet recruiting
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Treeline Biosciences, Inc.Updated: Jul 28, 2026Locations: 3
Eligibility criteria
Adults ≥18 years of age [+6]
Active brain metastases [+4]